

Kamal Mostafa  
Form 4  
March 06, 2018

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
Kamal Mostafa

2. Issuer Name and Ticker or Trading Symbol  
MAGELLAN HEALTH INC  
[MGLN]

5. Relationship of Reporting Person(s) to Issuer  
  
(Check all applicable)

(Last) (First) (Middle)  
  
15950 NORTH 76TH STREET, SUITE 200  
  
(Street)

3. Date of Earliest Transaction (Month/Day/Year)  
03/05/2018

\_\_\_ Director \_\_\_ 10% Owner  
 Officer (give title below) \_\_\_ Other (specify below)  
CEO, Magellan Rx Management

SCOTTSDALE, AZ 85260

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
\_\_\_ Form filed by More than One Reporting Person

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3)         | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |   |
|---|--------------------------------------|--|--------------------------------|---|---|--|---|---|
|   |                                      |  | Code                           | V   | Amount  | (D)  | Price   |   |
| Ordinary Common Stock, \$0.01 par value | 03/05/2018                           |  | X <sup>(1)</sup>               |   | 1,480   | A  | \$ 63.95 1,480  | D |
| Ordinary Common Stock, \$0.01 par value | 03/05/2018                           |  | X <sup>(1)</sup>               |   | 7,307   | A  | \$ 64.87 8,787  | D |
|   | 03/05/2018                           |  | X <sup>(1)</sup>               |   | 6,641   | A  | \$ 68.5 15,428  | D |

Ordinary  
Common  
Stock,  
\$0.01 par  
value

Ordinary  
Common  
Stock,  
\$0.01 par  
value

|            |                  |        |   |            |         |   |   |
|------------|------------------|--------|---|------------|---------|---|---|
| 03/05/2018 | S <sup>(1)</sup> | 15,428 | D | \$         | 99.0386 | 0 | D |
|            |                  |        |   | <u>(2)</u> |         |   |   |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) | 8. Amount or Number of Shares |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|-------------------------------|
| Stock Option (right to buy)                | \$ 63.95   | 03/05/2018                           |  | X <sup>(1)</sup>               | 1,480   | <sup>(3)</sup> 03/03/2025                                | Common Stock  | 1,480                         |
| Stock Option (right to buy)                | \$ 64.87   | 03/05/2018                           |  | X <sup>(1)</sup>               | 7,307   | <sup>(5)</sup> 03/03/2026                                | Common Stock  | 7,307                         |
| Stock Option (right to buy)                | \$ 68.5  | 03/05/2018                           |  | X <sup>(1)</sup>               | 6,641   | <sup>(6)</sup> 03/03/2027                                | Common Stock  | 6,641                         |

## Reporting Owners

| Reporting Owner Name / Address  | Relationships |           |                                |       |
|---|---------------|-----------|--------------------------------|-------|
|   | Director      | 10% Owner | Officer                        | Other |
| Kamal Mostafa<br>15950 NORTH 76TH STREET<br>SUITE 200<br>SCOTTSDALE, AZ 85260 |               |           | CEO, Magellan<br>Rx Management |       |

## Signatures

/s/ Mostafa

Kamal

03/06/2018

\*\*Signature of  
Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This transaction was effectuated pursuant to a Rule 10b-5-1 Plan.  
The number of securities reported represents an aggregate number of shares sold in multiple open market transactions at prices ranging from \$98.30 to \$101.05, inclusive. The price reported represents the weighted average price. The Reporting Person undertakes to provide
- (2) staff of the SEC, the issuer, or a stockholder of the issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.
- (3) All of the stock options in this tranche have vested in full.
- (4) Not applicable.
- (5) The remainder of 7,306 options shall vest on March 3, 2019.
- (6) The remainder of 13,282 options shall vest in equal increments on March 3, 2019 and 2020.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.